We analyzed 2901 AML patients with long-term follow-up treated with PETHEMA protocols in the pre-FLT3 inhibitors era, with 579 of them harboring the FLT3–ITD mutation. This evidence concerns the gene FLT3 and acute myeloid leukemia.